Verastem, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Verastem, Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000741). The filing signals that the institutional investor has crossed the key 5% beneficial ownership threshold in the clinical-stage biopharmaceutical company. Such 13G disclosures are typically passive holdings, distinguishing them from activist 13D filings. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further 13G amendments or 13D filings to gauge whether State Street's position remains passive or becomes active.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Verastem, Inc.